Nyxoah (XBRU:NYXH) Growth Rank : 0 (As of Jun. 08, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Nyxoah Growth Rank?

Nyxoah has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Nyxoah Growth Rank Related Terms

Thank you for viewing the detailed overview of Nyxoah's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Nyxoah (XBRU:NYXH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nyxoah SA (XBRU:NYXH) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

NYXH:USA 5YI:Germany

Address

Rue Edouard Belin 12, Mont-Saint Guibert, BEL, 1435

Website

https://www.nyxoah.com

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.